Harvard Bioscience (FRA:HBI) ROCE % : -13.70% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Harvard Bioscience ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Harvard Bioscience's annualized ROCE % for the quarter that ended in Mar. 2024 was -13.70%.

Harvard Bioscience ROCE % Historical Data

The historical data trend for Harvard Bioscience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Bioscience ROCE % Chart

Harvard Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-0.07

-1.71

1.07

-5.29

0.88

Harvard Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															7.10	-3.80	1.10	-1.08	-13.70

Harvard Bioscience ROCE % Calculation

Harvard Bioscience's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	0.949	/	( ( (137.22 - 21.947)	+	(125.965 - 24.339) )	/ 2 )
	=	0.949	/	( (115.273	+	101.626)	/ 2 )
	=	0.949	/	108.4495
	=	0.88 %

Harvard Bioscience's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-13.736	/	( ( (125.965 - 24.339)	+	(122.508 - 23.623) )	/ 2 )
	=	-13.736	/	( ( 101.626	+	98.885 )	/ 2 )
	=	-13.736	/	100.2555
	=	-13.70 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Harvard Bioscience (FRA:HBI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Harvard Bioscience ROCE % Related Terms

Thank you for viewing the detailed overview of Harvard Bioscience's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Harvard Bioscience (FRA:HBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (FRA:HBI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

HBIO:USA HBI:Germany

Address

84 October Hill Road, Holliston, MA, USA, 01746

Website

https://www.harvardbioscience.com

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.